絞り込み

16645

広告

Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma.

著者 Ishihara H , Takagi T , Kondo T , Fukuda H , Tachibana H , Yoshida K , Iizuka J , Kobayashi H , Okumi M , Ishida H , Tanabe K
Int J Clin Oncol.2019 Dec 19 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 0users)

Full Text Sources

The aim of this study was to compare the efficacy and safety of nivolumab as second-line and later-line (third-line or thereafter) therapy in metastatic renal cell carcinoma (mRCC).
PMID: 31858306 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード